Denosumab Products
Defines medical necessity, administration benefit assignment, and coverage criteria for denosumab products for osteoporosis, prevention of skeletal-related events, hypercalcemia of malignancy, and giant cell tumor of bone for Premera Blue Cross members and providers.
Preferred and non-preferred denosumab product designations were updated and criteria now require documented inadequate response or intolerance to specific preferred products before coverage of non-preferred products.
Dose limit of 120 mg every 4 weeks was added for prevention of skeletal-related events in individuals with multiple myeloma and bone metastases from solid tumors for a list of denosumab products.
Several denosumab biosimilars were designated as preferred products (Bildyos, Enoby, Bilprevda, Xtrenbo) and many other biosimilars moved to non-preferred status.
New HCPCS codes Q5161 and Q5162 were added to the coding section (effective April 1, 2026).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.